Your browser is no longer supported. Please, upgrade your browser.
Settings
PDSB PDS Biotechnology Corporation daily Stock Chart
PDSB [NASD]
PDS Biotechnology Corporation
Index- P/E- EPS (ttm)-2.34 Insider Own18.00% Shs Outstand15.19M Perf Week-3.70%
Market Cap19.75M Forward P/E- EPS next Y-2.74 Insider Trans0.00% Shs Float11.90M Perf Month-57.10%
Income-5.90M PEG- EPS next Q-0.93 Inst Own3.70% Short Float1.53% Perf Quarter-41.44%
Sales- P/S- EPS this Y38.30% Inst Trans5.84% Short Ratio1.89 Perf Half Y-78.04%
Book/sh2.97 P/B0.44 EPS next Y-94.30% ROA-21.00% Target Price8.50 Perf Year-83.95%
Cash/sh1.15 P/C1.13 EPS next 5Y- ROE-26.10% 52W Range1.29 - 11.80 Perf YTD-50.94%
Dividend- P/FCF- EPS past 5Y-34.70% ROI- 52W High-89.07% Beta1.97
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin- 52W Low0.00% ATR0.24
Employees14 Current Ratio5.00 Sales Q/Q- Oper. Margin- RSI (14)31.59 Volatility4.87% 11.26%
OptionableNo Debt/Eq0.00 EPS Q/Q59.70% Profit Margin- Rel Volume1.37 Prev Close1.30
ShortableYes LT Debt/Eq0.00 EarningsFeb 20 Payout- Avg Volume96.19K Price1.29
Recom2.00 SMA20-35.29% SMA50-44.96% SMA200-70.39% Volume94,846 Change-0.77%
Oct-24-19Initiated Chardan Capital Markets Buy $10
Feb-24-20 08:30AM  PDS Biotechnology Appoints Kamil Ali-Jackson, Esq. to Board of Directors GlobeNewswire
Feb-17-20 08:30AM  PDS Biotechnology to Present at Noble Capital Markets' 16th Annual Small & Microcap Investor Conference GlobeNewswire
Feb-14-20 04:05PM  PDS Biotechnology Corporation Announces Closing of Public Offering GlobeNewswire
Feb-12-20 09:18AM  The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga -25.84%
Feb-11-20 06:45PM  PDS Biotechnology Corporation Announces Pricing of Public Offering of Approximately $12 Million of Shares of Common Stock GlobeNewswire -12.32%
Feb-05-20 04:05PM  PDS Biotechnology to Present at the 2020 BIO CEO & Investor Conference GlobeNewswire -8.33%
Dec-11-19 04:15PM  PDS Biotechnology Announces Principal Investigator and Independent Data Monitoring Committee for its Phase 2 Clinical Collaboration with Merck GlobeNewswire
04:05PM  PDS Biotechnology Announces Resignation of James Loughlin from Board of Directors GlobeNewswire
Dec-03-19 08:40AM  PDS Biotechnology to Present at the 12th Annual LD Micro Main Event GlobeNewswire
Nov-25-19 08:30AM  PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 GlobeNewswire +7.55%
Nov-13-19 11:07AM  PDS Biotechnology (NASDAQ:PDSB) Will Have To Spend Its Cash Wisely Simply Wall St.
Nov-07-19 06:00AM  PDS Biotechnology Reports Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Nov-06-19 04:05PM  PDS Biotechnology Accepted for Oral Presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting GlobeNewswire
Oct-22-19 08:30AM  PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101 GlobeNewswire +10.71%
Oct-03-19 11:45AM  What's Behind PDS Biotech's Rally? Benzinga +31.33%
08:30AM  PDS Biotechnology Corp. Announces Clinical Collaboration with Merck GlobeNewswire
Oct-01-19 08:30AM  PDS Biotechnology Prioritizes Development of PDS0101 in Advanced Cancers Following Promising Phase 1 Clinical Outcome Data GlobeNewswire -5.82%
Sep-19-19 08:00AM  PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial GlobeNewswire +6.13%
Sep-03-19 08:30AM  PDS Biotechnology to Present at the 21st Annual H.C. Wainwright Global Investment Conference GlobeNewswire
Aug-01-19 06:00AM  PDS Biotechnology Reports Second Quarter 2019 Financial Results And Provides Business Update GlobeNewswire
Jul-03-19 08:30AM  PDS Biotechnology Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jun-19-19 08:30AM  PDS Biotechnology Corporation Granted U.S. and European Patents for Versamune® - GM-CSF Combination to Overcome Tumor Immune Suppression GlobeNewswire
May-29-19 09:41AM  Does PDS Biotechnology Corporation (NASDAQ:PDSB) Create Value For Shareholders? Simply Wall St.
08:30AM  PDS Biotechnology Signs Cooperative Research and Development Agreement with National Cancer Institute to Perform a Phase 2 Clinical Study of PDS0101 in Combination with Other Immune-modulating Agents in Advanced HPV-related Cancers GlobeNewswire
May-28-19 08:30AM  PDS Biotechnology to Present at the 9th Annual LD Micro Invitational GlobeNewswire
May-17-19 12:07PM  Learning When To Pick Your Battles Starts With Winning Setups Benzinga -6.74%
May-15-19 08:30AM  PDS Biotechnology Announces Publication Supporting Novel Mechanisms of Action of its Proprietary Versamune® Platform in Cancer Immunotherapy GlobeNewswire +41.37%
May-14-19 05:22PM  PDS Biotechnology: 1Q Earnings Snapshot Associated Press
04:10PM  PDS Biotechnology Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Apr-08-19 08:00AM  PDS Biotechnology Appoints Stephen Glover to its Board of Directors GlobeNewswire -8.86%
PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. The company develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its lead product candidate is PDS0101, a monotherapy first line therapy for cervical intraepithelial neoplasia of cancer. In addition, the company develops PDS0102, which is in Phase 2 clinical trial for treatment of prostate and breast cancers. Further, its pipeline product portfolio includes PDS0103 for treatment of colorectal, breast, ovarian, and lung cancers; and PDS 0104 for treatment of melanoma. Additionally, the company offers Versamune, a T-cell activating platform developed for immunotherapy approaches, such as checkpoint inhibitors, CAR-T cells and live-vector based vaccines, etc. The company has collaboration agreement with Merck and Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer. PDS Biotechnology Corporation was incorporated in 2009 and is based in Princeton, New Jersey.